Details of the Drug | DrugMAP

General Information of Drug (ID: DM704AN)

Drug Name

Sapacitabine

Synonyms

CYC682

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 3	[1]
Acute myeloid leukaemia	2A60	Phase 3	[2]
Breast cancer	2C60-2C65	Phase 2	[3]
Myelodysplastic syndrome	2A37	Phase 2	[1]
Ovarian cancer	2C73	Phase 2	[3]
Pancreatic cancer	2C10	Phase 2	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C26H42N4O5
Canonical SMILES: CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)C2C(C(C(O2)CO)O)C#N
InChI: 1S/C26H42N4O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-23(32)28-22-16-17-30(26(34)29-22)25-20(18-27)24(33)21(19-31)35-25/h16-17,20-21,24-25,31,33H,2-15,19H2,1H3,(H,28,29,32,34)/t20-,21+,24-,25+/m0/s1
InChIKey: LBGFKUUHOPIEMA-PEARBKPGSA-N

Cross-matching ID

PubChem CID: 153970
ChEBI ID: CHEBI:145429
CAS Number: 151823-14-2
TTD ID: D0D4RF

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01303796) A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)